Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Nanobiotix S.A.

$33.55 -2.30% NASDAQ: NBTX · 15-min delayed
  • Public · NASDAQ: NBTX
  • 97 employees
$1.8BMarket cap
97Employees
NBTXNASDAQ
2020IPO

About Nanobiotix S.A.

Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Market cap
$1.8B
NASDAQ: NBTX
$33.55 -2.30%

15-minute delayed · data by Polygon.io

Past year

$3.30 $55.07

52-week range

Market cap
$1.8B
Shares outstanding
53.6M
Open
Day range
Prev close
Volume
IPO date
Dec 11, 2020

Market data by Polygon.io · prices are 15-minute delayed

Auto-generated

At a glance

  • Trading 39% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Nanobiotix S.A..

Write a review
Newsroom

News about Nanobiotix S.A.

News & sentiment via Polygon.io

Explore

Similar companies

Browse all →